Content |
Assets
History
2024
Construction of factories for the production of pharmaceutical substances in Khimki for 1 billion rubles
On September 17, 2024, the Main Directorate of State Construction Supervision of the Moscow Region announced that the KhimRar group of companies had completed the creation of a complex for the production of pharmaceutical substances in Khimki. The total investment in the project exceeds 1 billion rubles.
The plant is located in the urban district Khimki on the territory of the KhimRar High Technologies Center, which already performs a full cycle of research, development and production of both import-substituting and innovative drugs of a new generation for the treatment of diseases of the central nervous system, oncology- HIV infection, as well as coronavirus, etc flu COVID-19. The project is supported by the Industrial Development Fund, the Russian Federation Ministry of Industry and Trade and. Moscow Region Government Permission for the construction of the facility was issued by Glavgosstroynadzor of the Moscow Region.
The complex will include the production of active pharmaceutical substances, warehouses, as well as a workshop for the development of intermediates for API. The new production line of API-Technologies will increase the capacity of the developer - KhimRar Group of Companies by more than five times. API-Technologies is a strategic division of the ChemRar Group of Companies, which allows to carry out a full cycle of production of pharmaceutical substances for innovative and reproduced synthetic drugs in accordance with Russian industry standards.
It is planned that substances will be produced at the new production site for innovative drugs from the company's current range against HIV infection and for the treatment of anxiety disorders, including those that arose after the coronavirus infection.
 | "The creation of its own technological line for the production of intermediates and active pharmaceutical substances in Russia is of important strategic importance for ensuring the drug safety of the country, especially against the background of logistical problems and difficulties with the supply of substances necessary for the production of drugs from abroad," the ChemRar Group said in a statement[1] |  |
Establishment of Khimskan
The pharmaceutical company ChemRar and the network of private clinics Medskan have joined forces to expand their presence on the international drug market. In mid-August 2024, it became known about the creation of the Khimskan joint venture, which will be engaged in the research and promotion of drugs in Russia and friendly countries. Read more here
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |